(Q34095473)

English

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study (English)

1 reference

Europe PubMed Central

31 July 2017

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

Olivier Hermine

23

1 reference

Europe PubMed Central

31 July 2017

Evelyne Callet-Bauchu

9

object named as

Evelyne Callet-Bauchu

1 reference

Europe PubMed Central

31 July 2017

object named as

Eva Hoster

2

0 references

object named as

Jan Walewski

17

0 references

object named as

Marek Trneny

16

0 references

Hanneke C Kluin-Nelemans

object named as

Hanneke C Kluin-Nelemans

22

0 references

8

object named as

Reiner Siebert

1 reference

Europe PubMed Central

31 July 2017

Wolfgang Hiddemann

20

object named as

Wolfgang Hiddemann

1 reference

Europe PubMed Central

31 July 2017

Christiane Pott

1

object named as

Christiane Pott

1 reference

Europe PubMed Central

31 July 2017

21

object named as

Michael Kneba

1 reference

Europe PubMed Central

31 July 2017

Jacques J M van Dongen

11

object named as

Jacques J M van Dongen

1 reference

Europe PubMed Central

31 July 2017

Martin Dreyling

25

object named as

Martin Dreyling

1 reference

Europe PubMed Central

31 July 2017

Michael Unterhalt

19

object named as

Michael Unterhalt

1 reference

Europe PubMed Central

31 July 2017

author name string

Marie-Helene Delfau-Larue

3

1 reference

Europe PubMed Central

31 July 2017

Kheira Beldjord

4

1 reference

Europe PubMed Central

31 July 2017

Sebastian Böttcher

5

1 reference

Europe PubMed Central

31 July 2017

Vahid Asnafi

6

1 reference

Europe PubMed Central

31 July 2017

Anne Plonquet

7

1 reference

Europe PubMed Central

31 July 2017

Niels Andersen

10

1 reference

Europe PubMed Central

31 July 2017

Wolfram Klapper

12

1 reference

Europe PubMed Central

31 July 2017

Françoise Berger

13

1 reference

Europe PubMed Central

31 July 2017

Vincent Ribrag

14

1 reference

Europe PubMed Central

31 July 2017

Achiel L van Hoof

15

1 reference

Europe PubMed Central

31 July 2017

Peter Dreger

18

1 reference

Europe PubMed Central

31 July 2017

Elizabeth Macintyre

24

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

23 December 2009

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

115

1 reference

Europe PubMed Central

31 July 2017

3215-3223

1 reference

Europe PubMed Central

31 July 2017

16

1 reference

Europe PubMed Central

31 July 2017

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

A concordance correlation coefficient to evaluate reproducibility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

5 July 2018

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2930903

28 October 2018

The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20032498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall s

1 reference

https://pubmed.ncbi.nlm.nih.gov/20032498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20032498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20032498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting

1 reference

https://pubmed.ncbi.nlm.nih.gov/20032498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20032498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20032498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/20032498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20032498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2009-06-230250

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34095473&oldid=2092777229"